Cerenome signs in-network deal with Blue Cross Blue Shield of Michigan for CNSide test
Bitget2026/09/22 11:30- Cerenome signed an in-network provider agreement with Blue Cross Blue Shield of Michigan for its CNSide CSF tumor cell enumeration assay.
- Contract took effect Sept. 1, 2026; BCBSM serves about 5 million commercial and Medicare Advantage members.
- Agreement lifts CNSide contracted reimbursement coverage to about 158 million commercial and Medicare Advantage covered lives.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
JPMorgan raises target prices for Target and Walmart
Orient Precision Industries Holds Extraordinary Shareholders Meeting
Crypto prices
More
